372102-30-2

Upstream product

• 69455-12-5 4-benzyloxy-3-bromobenzaldehyde 
• 103797-05-3 N-(3-acetyl-2-hydroxy-5-methyl-phenyl)-acetamide 
• 351-54-2 3-fluoro-p-anisaldehyde 
• 66108-30-3 2-hydroxy-5-methyl-3-nitroacetophenone 
• 64-17-5 ethanol 
• 13246-46-3 2,4-dibenzyloxybenzaldehyde 
• 34328-61-5 3-Chloro-4-fluorobenzaldehyde 

Downstream Products

• 372102-31-3 N-{2-[4-(benzyloxy)-3-bromophenyl]-3-hydroxy-6-methyl-4-oxo-4H-chromen-8-yl}acetamide 
• 372102-79-9 C₃₄H₂₈F₃NO₆S 
• 372102-50-6 2-(benzyloxy)-5-[3-(benzyloxy)-8-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-6-methyl-4-oxo-4H-chromen-2-yl]benzonitrile 
• 372102-35-7 C₃₃H₂₈BrNO₆S 
• 372102-34-6 8-amino-3(benzyloxy)-2-[4-(benzyloxy)-3-bromophenyl]-6-methyl-4H-chromen-4-one 
• 372102-33-5 N-{3-(benzyloxy)-2-[4-(benzyloxy)-3-bromophenyl]-6-methyl-4-oxo-4H-chromen-8-yl}acetamide 

Relevant academic research and scientific papers

3-Hydroxychromones as cyclin-dependent kinase inhibitors: Synthesis and biological evaluation

A novel series of 3-hydroxychromones were prepared and found to be CDK inhibitors. Isothiazolidine 1,1-dioxide analogues showed potent CDK1 and CDK2 inhibitory activities and inhibited proliferation of EJ, HCT116, SW620, and MDAMB468 cancer cells.

Cdk inhibitors having 3-hydroxychromen-4-one structure

The present invention relates to a novel 3-hydroxychromen-4-one derivative of formula (1), pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase (“CDK”); to a process for preparing the compound of formula (1); and to a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. comprising the compound of formula (1) as an active component together with pharmaceutically acceptable carriers.